Intravenous Immunoglobulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Intravenous Immunoglobulin Market is projected to expand from USD 13.41 Billion in 2025 to USD 21.01 Billion by 2031, registering a compound annual growth rate of 7.77%. Derived from the pooled plasma of thousands of healthy donors, Intravenous Immunoglobulin (IVIg) serves as a critical treatment for patients suffering from primary immunodeficiency diseases and autoimmune disorders. The market's foundation is strengthened by the increasing prevalence of diagnosed immune deficiencies and an aging global demographic requiring immune modulation. Additionally, the broadening clinical use of IVIg for neurological conditions functions as a fundamental driver of growth, extending beyond temporary trends or immediate regulatory changes.

However, the industry faces substantial hurdles related to the intricate and expensive logistics necessary to secure enough source plasma to satisfy rising global demand. For instance, the National Blood Authority reported that in 2024, approximately 9.3 million grams of immunoglobulin products were issued in Australia during the 2023-24 fiscal year, underscoring the immense strain on supply chains to keep pace with consumption. Consequently, the challenge of rapidly expanding plasma collection infrastructure stands as a major obstacle to further market growth.

Market Drivers

The primary catalyst for market growth is the increasing diagnosis of primary and secondary immunodeficiency disorders. As healthcare systems refine their ability to detect compromised immune function, a larger patient population requires lifelong immunoglobulin replacement therapies to prevent infections. This establishes a consistent demand baseline that necessitates continuous capacity expansion by plasma fractionators. For example, CSL Limited reported in their August 2024 Annual Report that immunoglobulin portfolio sales increased by 20% to $5.66 billion, highlighting the critical need for these biological treatments among diagnosed patients.

Concurrently, the rising demand for intravenous immunoglobulin in treating neurological conditions, particularly autoimmune neuropathies such as Chronic Inflammatory Demyelinating Polyneuropathy, is significantly expanding the therapeutic landscape. Regulatory endorsements in this area are driving utilization, leading to higher competition for limited plasma resources. According to a January 2024 press release from Takeda, pivotal trial data showed a relapse rate of just 15.5% for patients on therapy compared to 31.7% for the placebo group, confirming its efficacy. This clinical success supports financial growth, as evidenced by Grifols reporting biopharmaceutical revenue of EUR 5.55 billion in 2024, driven largely by strong immunoglobulin adoption.

Market Challenges

The Global Intravenous Immunoglobulin Market faces significant constraints due to the sophisticated and capital-intensive logistics needed to obtain adequate volumes of source plasma. Unlike pharmaceutical industries that utilize synthetic manufacturing, the IVIg sector is bound by the biological limitations of human donation and the extensive infrastructure required for collection, testing, and transport. This reliance results in a rigid supply chain where production capabilities cannot be rapidly scaled to meet the increasing international demand for autoimmune and immunodeficiency treatments, effectively limiting market expansion.

As a result, this supply bottleneck hinders the sector's capacity to leverage rising diagnosis rates. The amount of raw material necessary to support a single patient is extensive, placing constant pressure on collection networks to expand at a difficult pace. The Plasma Protein Therapeutics Association noted in 2024 that treating one patient with primary immune deficiency requires about 130 plasma donations per year. This high-volume requirement underscores the significant logistical challenges in scaling operations; as clinical demand rises, the industry finds it difficult to proportionally increase collection capacity, which directly impacts product availability and overall market growth.

Market Trends

A significant evolution in the market is the technological optimization of plasma fractionation yields. Confronted with the biological limitations of sourcing raw plasma, manufacturers are actively deploying advanced fractionation methods to maximize immunoglobulin protein recovery from each donation. This emphasis on operational efficiency enables companies to separate production volumes from the need for linear increases in plasma collection, thereby stabilizing margins and enhancing supply resilience. For instance, Grifols stated in February 2024 that their Operational Improvement Plan led to a 22% reduction in plasma cost per liter by December 2023 compared to the July 2022 peak, illustrating the financial benefits of these yield-improving technologies.

Simultaneously, there is a widespread shift toward the adoption of home-based IVIg infusion therapies, fueled by patient preference for convenience and payer demand for cost-efficient care settings. This trend decentralizes administration, moving treatment from inpatient hospitals to specialized ambulatory and home infusion networks that provide flexible scheduling and lower infection risks. This structural change is driving the growth of independent providers in the remote infusion space. As evidence of this shift, Option Care Health reported in October 2024 that third-quarter net revenue reached $1.27 billion, a 17.0% increase year-over-year, reflecting the escalating demand for home and alternate site infusion services.

Key Players Profiled in the Intravenous Immunoglobulin Market

• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products Holdings Inc.
• CSL Behring
• Grifols SA
• Kedrion SpA
• Shanghai RAAS Blood Products Co. Ltd.
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxter International Inc

Report Scope

In this report, the Global Intravenous Immunoglobulin Market has been segmented into the following categories:

Intravenous Immunoglobulin Market, by Type:

• IgG
• IgA
• IgM
• IgE
• IgD

Intravenous Immunoglobulin Market, by Application:

• Hypogammaglobulinemia
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Primary Immunodeficiency Diseases
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• Other Applications

Intravenous Immunoglobulin Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intravenous Immunoglobulin Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.